Ask AI
PI3K and AKT Inhibitors for Advanced HR Pos BC

CE / CME

Treatment Selection for the Management of Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer and PIK3CA/AKT1/PTEN Alterations

European Learners: 0.50 EBAC® CE Credit

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: February 13, 2026

Expiration: August 12, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your patient with HR+/HER2- advanced recurrent metastatic breast cancer (MBC) and PIK3CA mutation has begun experiencing increasing fasting blood glucose levels on laboratory results after starting treatment with an inavolisib-based regimen. The patient had no known risk factors for diabetes or hyperglycemia at treatment start. Her fasting blood glucose was 115 mg/dL (A1C 4.8%) at baseline and fasting blood glucose is now 155 mg/dL after 3 months of receiving inavolisib-based therapy.

Which of the following prescribing information recommendations would you take into consideration for addressing the rising levels in fasting blood glucose in this patient?

2.

Which of the following can help inform the selection of inavolisib with palbociclib and fulvestrant in a patient with hormone receptor–positive (HR+)/HER2-negative (HER2-) locally advanced or metastatic breast cancer that previously received adjuvant therapy?